Cargando…
Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility
The ketone body 3-hydroxybutyrate (3-OHB) increases cardiac output and myocardial perfusion without affecting blood pressure in humans, but the cardiovascular sites of action remain obscure. Here, we test the hypothesis in rats that 3-OHB acts directly on the heart to increase cardiac contractility...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492777/ https://www.ncbi.nlm.nih.gov/pubmed/37688627 http://dx.doi.org/10.1007/s00395-023-01008-y |
_version_ | 1785104329310470144 |
---|---|
author | Homilius, Casper Seefeldt, Jacob Marthinsen Axelsen, Julie Sørensen Pedersen, Tina Myhre Sørensen, Trine Monberg Nielsen, Roni Wiggers, Henrik Hansen, Jakob Matchkov, Vladimir V. Bøtker, Hans Erik Boedtkjer, Ebbe |
author_facet | Homilius, Casper Seefeldt, Jacob Marthinsen Axelsen, Julie Sørensen Pedersen, Tina Myhre Sørensen, Trine Monberg Nielsen, Roni Wiggers, Henrik Hansen, Jakob Matchkov, Vladimir V. Bøtker, Hans Erik Boedtkjer, Ebbe |
author_sort | Homilius, Casper |
collection | PubMed |
description | The ketone body 3-hydroxybutyrate (3-OHB) increases cardiac output and myocardial perfusion without affecting blood pressure in humans, but the cardiovascular sites of action remain obscure. Here, we test the hypothesis in rats that 3-OHB acts directly on the heart to increase cardiac contractility and directly on blood vessels to lower systemic vascular resistance. We investigate effects of 3-OHB on (a) in vivo hemodynamics using echocardiography and invasive blood pressure measurements, (b) isolated perfused hearts in Langendorff systems, and (c) isolated arteries and veins in isometric myographs. We compare Na-3-OHB to equimolar NaCl added to physiological buffers or injection solutions. At plasma concentrations of 2–4 mM in vivo, 3-OHB increases cardiac output (by 28.3±7.8%), stroke volume (by 22.4±6.0%), left ventricular ejection fraction (by 13.3±4.6%), and arterial dP/dt(max) (by 31.9±11.2%) and lowers systemic vascular resistance (by 30.6±11.2%) without substantially affecting heart rate or blood pressure. Applied to isolated perfused hearts at 3–10 mM, 3-OHB increases left ventricular developed pressure by up to 26.3±7.4 mmHg and coronary perfusion by up to 20.2±9.5%. Beginning at 1–3 mM, 3-OHB relaxes isolated coronary (EC(50)=12.4 mM), cerebral, femoral, mesenteric, and renal arteries as well as brachial, femoral, and mesenteric veins by up to 60% of pre-contraction within the pathophysiological concentration range. Of the two enantiomers that constitute racemic 3-OHB, D-3-OHB dominates endogenously; but tested separately, the enantiomers induce similar vasorelaxation. We conclude that increased cardiac contractility and generalized systemic vasorelaxation can explain the elevated cardiac output during 3-OHB administration. These actions strengthen the therapeutic rationale for 3-OHB in heart failure management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-023-01008-y. |
format | Online Article Text |
id | pubmed-10492777 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-104927772023-09-11 Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility Homilius, Casper Seefeldt, Jacob Marthinsen Axelsen, Julie Sørensen Pedersen, Tina Myhre Sørensen, Trine Monberg Nielsen, Roni Wiggers, Henrik Hansen, Jakob Matchkov, Vladimir V. Bøtker, Hans Erik Boedtkjer, Ebbe Basic Res Cardiol Original Contribution The ketone body 3-hydroxybutyrate (3-OHB) increases cardiac output and myocardial perfusion without affecting blood pressure in humans, but the cardiovascular sites of action remain obscure. Here, we test the hypothesis in rats that 3-OHB acts directly on the heart to increase cardiac contractility and directly on blood vessels to lower systemic vascular resistance. We investigate effects of 3-OHB on (a) in vivo hemodynamics using echocardiography and invasive blood pressure measurements, (b) isolated perfused hearts in Langendorff systems, and (c) isolated arteries and veins in isometric myographs. We compare Na-3-OHB to equimolar NaCl added to physiological buffers or injection solutions. At plasma concentrations of 2–4 mM in vivo, 3-OHB increases cardiac output (by 28.3±7.8%), stroke volume (by 22.4±6.0%), left ventricular ejection fraction (by 13.3±4.6%), and arterial dP/dt(max) (by 31.9±11.2%) and lowers systemic vascular resistance (by 30.6±11.2%) without substantially affecting heart rate or blood pressure. Applied to isolated perfused hearts at 3–10 mM, 3-OHB increases left ventricular developed pressure by up to 26.3±7.4 mmHg and coronary perfusion by up to 20.2±9.5%. Beginning at 1–3 mM, 3-OHB relaxes isolated coronary (EC(50)=12.4 mM), cerebral, femoral, mesenteric, and renal arteries as well as brachial, femoral, and mesenteric veins by up to 60% of pre-contraction within the pathophysiological concentration range. Of the two enantiomers that constitute racemic 3-OHB, D-3-OHB dominates endogenously; but tested separately, the enantiomers induce similar vasorelaxation. We conclude that increased cardiac contractility and generalized systemic vasorelaxation can explain the elevated cardiac output during 3-OHB administration. These actions strengthen the therapeutic rationale for 3-OHB in heart failure management. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00395-023-01008-y. Springer Berlin Heidelberg 2023-09-09 2023 /pmc/articles/PMC10492777/ /pubmed/37688627 http://dx.doi.org/10.1007/s00395-023-01008-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Contribution Homilius, Casper Seefeldt, Jacob Marthinsen Axelsen, Julie Sørensen Pedersen, Tina Myhre Sørensen, Trine Monberg Nielsen, Roni Wiggers, Henrik Hansen, Jakob Matchkov, Vladimir V. Bøtker, Hans Erik Boedtkjer, Ebbe Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility |
title | Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility |
title_full | Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility |
title_fullStr | Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility |
title_full_unstemmed | Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility |
title_short | Ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility |
title_sort | ketone body 3-hydroxybutyrate elevates cardiac output through peripheral vasorelaxation and enhanced cardiac contractility |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492777/ https://www.ncbi.nlm.nih.gov/pubmed/37688627 http://dx.doi.org/10.1007/s00395-023-01008-y |
work_keys_str_mv | AT homiliuscasper ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT seefeldtjacobmarthinsen ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT axelsenjuliesørensen ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT pedersentinamyhre ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT sørensentrinemonberg ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT nielsenroni ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT wiggershenrik ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT hansenjakob ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT matchkovvladimirv ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT bøtkerhanserik ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility AT boedtkjerebbe ketonebody3hydroxybutyrateelevatescardiacoutputthroughperipheralvasorelaxationandenhancedcardiaccontractility |